62 min listen
Episode 69
FromBiotech Hangout
ratings:
Length:
60 minutes
Released:
Aug 17, 2023
Format:
Podcast episode
Description
On Biotech Hangout this week, Brad Loncar, Chris Garabedian, Sam Fazeli, Rob Perez and Ethan Perlstein discuss the influence of GLP-1s including cost, safety, drawbacks and more in light of Novo Nordisk’s positive semaglutide SELECT study results and Eli Lilly’s earnings, which rose due to their type 2 diabetes drug. Other big topics include last week’s Sage and Biogen news following the FDA’s decision to approve zuranolone for PPD but not MDD and its effect on Sage’s stock, plus progress and setbacks in ultra rare diseases including Taysha Gene Therapies. The hosts also dive into Iveric Bio’s drug approval for geographic atrophy, Nektar suing Eli Lilly over botched data, Bluebird Q2 earnings, Mirati data and the 3rd annual Timmerman Traverse. *This episode aired on August 11, 2023
Released:
Aug 17, 2023
Format:
Podcast episode
Titles in the series (72)
Pre-ASCO Discussion: Perspectives on Emerging Oncology Treatments by Biotech Hangout